PubMed · 15770816
[Inflammatory bowel diseases].
Abstract
COX-2 specific anti-inflammatory agents appear as able to induce a flare of inflammatory bowel disease as classical anti-inflammatory agents. The use of steroids, immunomodulators or infliximab prior to surgery does not appear to increase post-operative complication rates. Cases of hepatitis B reactivation have been described after infliximab therapy, suggesting that hepatitis B serological status should be verified prior to infliximab therapy. Adalimubab, a fully humanized antibody directed against TNF-alpha, is efficacious in patients that have lost response or did not tolerate infliximab. Approval of this agent is still awaited. Leucoapheresis is a promising tool in ulcerative colitis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
C Felley, J Guyot, J Hess, C Mottet, J Delarive, P Michetti. 2005-01-19. [Inflammatory bowel diseases].. https://pubmed.ncbi.nlm.nih.gov/15770816/
Cite the original work for its findings. Save a collection to share your selection of sources.